Is AMGN a good stock to buy?
We came across a bullish thesis on Amgen Inc. on r/investing_discussion by Variant_Invest
In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.’s share was trading at $344.57 as of June 9th. AMGN’s trailing and forward P/E were 23.98 and 15.48 respectively according to Yahoo Finance.
Pressmaster/ Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. AMGN is facing a widely acknowledged loss-of-exclusivity (LOE) cliff, with legacy assets such as Enbrel already in decline and Otezla under competitive pressure, yet the market narrative appears to underappreciate the strength and diversification of its replacement engine. 15 AI Stocks That Are Quietly Making Investors Rich Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential While consensus frames the upcoming erosion as a structural earnings reset, Amgen’s biosimilars platform has already evolved into a meaningful profit contributor, leveraging decades of biologics manufacturing expertise that creates a durable barrier to entry and positions the company as both incumbent and competitor in the same high-value therapeutic categories. This structural shift meaningfully alters the downside profile of the LOE cycle.